Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
February 10, 2021 02:45 ET
|
Junshi Biosciences
Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19More than...
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
February 01, 2021 07:53 ET
|
Junshi Biosciences
Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option...
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
January 26, 2021 10:35 ET
|
Junshi Biosciences
Trial met primary endpoint and key secondary endpoints with high statistical significanceResults from more than 1,000 high-risk patients were consistent with previous dataIn November, Lilly submitted...
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
January 24, 2021 19:07 ET
|
Junshi Biosciences
SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
December 28, 2020 20:22 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
December 13, 2020 19:00 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate
December 01, 2020 00:13 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006
November 30, 2020 18:55 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints
October 07, 2020 22:50 ET
|
Junshi Biosciences
-- Viral load, symptoms, and hospitalizations or ER visits reduced -- Request for EUA and BLA filings for the combination therapy anticipated in Nov 2020 and as early as 2Q2021, respectively-- Large...
JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma
September 28, 2020 22:35 ET
|
Junshi Biosciences
SHANGHAI, China, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...